AMP 2018 Annual Meeting Recordings (+SAM) - AMP - Online Learning by AMP

This collection includes access to the sessions recorded at the 2018 Annual Meeting presentations, the associated pdf slides, and SAM Credit for select talks

See the topics tab or click here for a complete list of available talks and SAM eligible talks.


AMP is the leading organization in the field of molecular diagnostics, and the AMP Annual meeting is the premier gathering of molecular professionals. As technologies change and new challenges arise, members and non-members alike rely on the AMP meeting to obtain the critical information needed to ensure that their patients receive the best care and best results.

Many of the sessions from the AMP Annual Meeting and Expo were recorded and this collection contains all the recorded sessions and downloadable PDF slides. See the "topics" tab for a list of all the presentations for which recordings and slides are available.

Duration of Recording: 49.25 hrs total

Last day to purchase and claim credit: November 1, 2019

Maximum SAM credit available: 14.25 hrs

You can purchase individual session recordings + SAM ($60 for members, $199 for nonmembers) or all of the AMP 2018 Annual Meeting Recordings + SAM for a significant discount ($525 for members, $749 for nonmembers).

  • To purchase all the session recordings, click the "Add to Basket" button located on the right.
  • To purchase individual talks, click on the "Purchase Individual Topics" button on the right, click on the titles to expand, and select the "add" button for the session(s) that you would like to purchase.

If you have questions, please email AMPeducation@amp.org


HOW TO CLAIM SAM:

To earn SAM credit, all learners must watch the webinars, achieve a minimum score of 75-80% on the online quiz, and complete the online survey. To access the quiz and survey click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left.

Click here for detailed instructions on how to claim SAM.

 

SAM Credit

This course is approved by the American Board of Pathology for 14.25 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

* You may not submit SAMs and CME/CMLE credit for the same content.


Note: Join the AMP Family to purchase this content for a deep discount!

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


How to access the recordings

  1. Click here for instructions on how to access the presentation slides.

 

Join the AMP Family for a discount on this item.

 
Course Information
Course Date:
November 01, 2018
Click on a topic name to see details and purchase options.
Thursday November 1, 2018

AMP Annual Meeting 2018 - Program Book

Also available here: https://amp18.amp.org/program/program/

Not Available for Individual Purchase

Genomics of Pediatric AML and MDS

Jeffery Klco, MD, PhD, St Jude Children's Research Hospital, Memphis, TN, USA

Session Description: We will discuss the recent advances in the genomic characterization of pediatric AML and MDS. In particular, we will discuss the differences observed between these diseases in children and adults and how some subtypes of AML/MDS are enriched in different age groups. A commentary on how these pediatric lesions can be used to detect minimal residual disease or guide therapy will be included. Lastly, we will discuss recent work on different germline lesions found in pediatric AML and MDS.

Session Objectives:

  • Summarize the genomic differences between pediatric and adult AML.
  • Discuss the development of MDS in children.
  • Compare different MRD approaches in children with AML.

Duration: 1 hr

Recording Date: November 1, 2018

SAM credit available: 1 hr

Last day to purchase course and claim credit: November 1, 2019

SAM EDITOR: Catherine Cottrell, PhD

ProductAddPrice
Klco (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Large Indel Detection in Clinical NGS Assays
Sabah Kadri, PhDAnn & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA

Session Description: Detection of Insertion and Deletion (Indel) variants from next generation sequencing (NGS) data is challenging for current technologies and software. The problem is further compounded by laboratory approaches (e.g. the type of sequence chemistry) and the specific variant context (e.g. complex variants and difficult genomic regions). This session will discuss the various challenges and novel bioinformatics strategies to enhance the detection of Indel variants from NGS data.

Session Objectives:

  • Summarize the challenges of general purpose variant calling for detection of Indel variants.
  • Discuss bioinformatics strategies to improve Indel detection sensitivity from NGS data.

Duration: 1 hr

Recording Date: November 1, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Kadri
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Vincent Magrini, PhD, Institute for Genomic Medicine (IGM) at Nationwide Children's Hospital, Columbus, OH, USA

Catherine E. Cottrell PhD PhD, Nationwide Children's Hospital, Columbus, OH, USA

Session Description: Laboratories are increasingly utilizing complementary sequencing technologies for augmentation of data in difficult to characterize genomic regions. This session aims to examine the utility of generating long read data, including single molecule real-time sequencing and linked reads, to elucidate structural variant composition, detect fusion transcripts, quantify repeat expansions, resolve phasing, and improve mapping in repetitive regions. Optimization of such technologies in a development setting paves the way for translational and clinical applications.

Session Objectives:

  • Review the advantages of single molecule sequencing, including generating long read lengths to characterize structural variation.
  • Describe the third-generation sequencing technologies, including single molecule real-time (SMRT) sequencing and nanopore sequencing, and how these technologies can also detect fusion transcripts, quantify repeats, resolve phasing, and improve mapping of repetitive regions.
  • Identify new applications for these optimized sequencing methods in translational research and clinical diagnostic fields.

Duration: 1 hr

Recording Date: November 1, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Magrini & Cottrell
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Validation of the Karius Microbial Cell-free DNA Sequencing Test for Infectious Disease
Timothy A. Blauwkamp, PhD, Karius, Inc., Redwood City, CA, USA

A Smart Diagnostic: Technology that Learned to Identify and Count Individual Bacteria in Blood
Stephanie I. Fraley, PhD, University of California, San Diego, CA, USA 
Speaker did not provide permission to share her presentation.

Session Description: This session is dedicated to presentations of unique and state-of-the-art molecular methods for the detection and quantitation of infectious disease organisms in patient samples.

Session Objectives:

  • Describe the unique advantages of using microbial cell-free DNA sequencing to identify infectious diseases.
  • Discuss results from analytical and clinical validations of quantitative microbial cfDNA sequencing tests.
  • Outline the new integrative technology called “Universal Digital High Resolution Melt,” which unites the advantages of digital PCR, high resolution melting of DNA, and machine learning to detect infectious microbes.  

Duration: 0.5 hr

Recording Date: November 1, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Blauwkamp
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Occurrence of Medulloblastoma in a Patient with Curry-Jones Syndrome
Binu Porath, PhD, Children's Mercy Hospital, Kansas City, MO, USA

Identification of a Novel Likely Pathogenic PIK3R1 Variant by Targeted Next-Generation Sequencing Analysis in a Patient with Overgrowth Syndrome and Lymphatic Malformation
Christopher Suciu, MD, MS Washington University School of Medicine in St. Louis, St. Louis, MO, USA

Sex Check: Verifying Patient Sex Based on Off-Panel SNPs on the X Chromosome
Jennifer Bynum, MD, Johns Hopkins, Baltimore, MD, USA

A Discrepancy Between the Human Reference Genome (GRCh37) and Transcriptome (RefSeq) Results in the Incorrect Annotation of a Clinically-Relevant Sequence Variant in RECQL4
Lisa Lansdon, PhD, Children's Mercy Kansas City, Kansas City, MO, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case’s clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 1 hr

Recording Date: November 1, 2018

SAM available: SAM is not available for this session

ProductAddPrice
CS Genetics/Info
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Jonathan Rothberg, PhD, Founder, Chairman, and CEO of Butterfly Network, Inc. CT, USA

Session Description: Jonathan Rothberg had just taken his first company public when his newborn son Noah began experiencing difficulty breathing. Terrified and desperate for answers, Rothberg vowed to build a machine that would tell him what was wrong with his son. Scientist, serial entrepreneur and father, Rothberg shares his quest to democratize healthcare through innovation. From the invention and commercialization of high-throughput “nextgen” genome sequencing to the creation of the Ultrasound-on-a-Chip, Rothberg describes the industry-disrupting power of semiconductors and machine learning, and reveals how his innovations helped decode the Neanderthal genome, give birth to precision medicine, and democratize access to personalized healthcare.

Session Objectives: 

  • Describe the historical and scientific context surrounding the invention of “next-generation” sequencing and its early applications.
  • Describe the clinical value of AI-enabled ultrasound-on-chip as a diagnostic tool.

Duration: 1.25 hr

Recording Date: November 1, 2018

SAM available: 1.25 hr

Last day to purchase course and claim credit: November 1, 2019 

SAM Editor: Alan Brown, MD

ProductAddPrice
Rothberg (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Newborn Genomic Sequencing for Diagnosis and Screening
Jonathan S. Berg, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

The Babyseq Project: A Study of Newborn Genomic Sequencing
Ingrid A. Holm, MD, MPH, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA

Session Description: Dramatic advances in next-generation sequencing (NGS) have made it possible to consider extending this technology to newborn screening (NBS). This session will identify ways in which NGS could be used to augment NBS, as well as technical challenges and Ethical/Legal/Social issues encountered in the NSIGHT studies that would need to be addressed in order for NGS-NBS to be widely adopted.

Session Objectives:

  • Describe differences between the use of sequencing in a diagnostic setting versus screening.
  • Summarize challenges involved in the informed consent process for newborn sequencing.
  • Discuss viewpoints on the likely implementation of newborn sequencing in the future. 

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Berg&Holm
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Viral Genomics in the Clinical Lab
Alex Greninger, MD, PhD, University of Washington, Seattle, WA, USA

NGS for Natural Disasters
Randall Olsen, MD, PhD, Houston Methodist Hospital and Research Institute, Houston, TX, USA

Session Description: This session will cover the challenges and opportunities of using a whole genome molecular epidemiology method (NextGen Sequencing ) to investigate the epidemiology of infectious diseases. Situations including outbreaks and natural disasters will be discussed.

Session Objectives:

  • Describe how whole genome sequencing allows unprecedented resolution for tracking infectious disease transmission.
  • Discuss investigations from large public health outbreaks of food borne illness to local hospitalacquired infections.
  • Summarize the clinical utility of whole genome sequencing of microbes to identify organisms with uncertain taxonomic origin and to investigate molecular bases of unusual antimicrobial resistance or virulence phenotypes. 

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Greninger&Olsen
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Leveraging Computer Infrastructure to Scale Clinical Bioinformatics
Elaine Gee, PhD, BigHead Analytics Group, Windsor, CA, USA

Standards and Apps for Genomic Decision Support
Jeremy L. Warner, MD, MS, Vanderbilt University, Nashville, TN, USA

Session Description: Informatics has solidified itself as an important subdiscipline within the molecular pathology community. However, it is still often siloed from one laboratory to the next and even from the laboratory to the rest of the healthcare environment. Standards and new technologies are now developing or being applied in other industries that will enable molecular informatics to be interconnected across many arenas. This session will provide detail on some of these cutting-edge standards and technologies, specifically workflow languages, container infrastructure such as Docker, and the FHIR standard for relaying genomic findings to the electronic health records.

Session Objectives:

  • Describe emerging technologies and standards in the clinical informatics space.
  • Examine how these technologies can be implemented within a molecular diagnostics laboratory and where in the clinical testing process they can be implemented.
  • Discuss how the standards fit into the broader healthcare infrastructure and ecosystem to support precision medicine.

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available: 0.75 hr (Only Elaine Gee's talk is eligible for SAM)

Last day to purchase course and claim credit: November 1, 2019 

SAM EDITORS: Cory Broehm, MD

ProductAddPrice
Gee&Warner (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Elizabeth Swisher, MD, University of Washington, Seattle, WA, USA

Stephen Lincoln, Invitae, San Francisco, CA, USA

Eric H. Bernicker, MD, Houston Methodist Hospital, Houston, TX, USA

Valentina Nardi, Massachusetts General Hospital, Boston, MA, USA

Jonathan A. Nowak, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

Angela Jacobson, MS, University of Washington, Seattle, WA, USA

Session Description: Precision medicine demands a team effort to ensure accurate diagnosis, appropriate genomic testing, and integration of tumor and germline genetic findings into a comprehensive plan for optimal patient care. In this session, a multidiscipinary team including pathologists, oncologists, molecular diagnosticians, and informaticians will tackle two real-life clinical challenges. These case-based sessions will examine the performance of different technologies in the detection of challenging but clinically important genomic variants, the critical role of bioinformatics in detection and annotation of DNA variants, and the ultimate clinical implications.

Session Objectives:

  • Recognize approaches to detection and interpretation of hereditary cancer predisposition gene variants in adult cancer patients.
  • Summarize technical approaches for the detection of insertion-deletion events using DNA and RNA-based next generation sequencing methods.
  • Discuss best practices for accurate and informative annotation of novel or ambiguous variants. 

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Molecular Tumor Board
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Spliceosome Gene Mutations in MDS
Matthew Walter, MD, Washington University, St. Louis, MO, USA

Inherited Hematopoietic Malignancies
Lucy A. Godley, MD, PhD, The University of Chicago, Chicago, IL, USA

Session Description: This session will describe inherited mutations that confer an increased risk for the development of hematopoietic malignancies. We will cover the World Health Organization’s provisional category for germline predisposition to myeloid malignancies as well as what is known regarding predisposition to lymphoid malignancies. We will also discuss the detection of germline mutations from next-generation sequencing panels used in prognostication of acute leukemias. Acquired mutations in genes that code for core components of the spliceosome are common in several hematopoietic malignancies. This session will also review what is known about altered RNA splicing and abnormal hematopoiesis induced by spliceosome gene mutations. In addition, we will discuss novel therapeutic strategies to target spliceosome mutant cells in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Session Objectives:

  • Outline the current WHO classification for germline predisposition to myeloid malignancies.
  • Describe ways in which molecular profiling can be used to detect a germline syndrome.
  • Discuss ongoing variant curation by the ClinGen Myeloid Malignancy Committee.
  • Define the spliceosome genes that are commonly mutated in MDS and AML.
  • Summarize the types of RNA splicing alterations induced by spliceosome gene mutations.
  • Recognize novel treatment approaches for patients with spliceosome gene mutations. 

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available: 1.5 hr

Last day to purchase course and claim credit: November 1, 2019 

SAM Editor: Kristin Karner, MD

ProductAddPrice
Walter&Godley (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Are Meningitis/Encephalitis Panels Ready for Prime Time?
Kevin Alby, PhD, University of Pennsylvania, Philadelphia, PA, USA

Point-Counterpoint: Molecular Diagnosis of Meningitis/Encephalitis
Jennifer Dien Bard, PhD, Children's Hospital Los Angeles, Los Angeles, CA, USA
University of Southern California, Los Angeles, CA, USA

Session Description: In most incidences, syndromic testing has been a welcome addition to many clinical laboratories. In contrast, the meningitis/encephalitis (ME) panel by been met with polarizing viewpoints. It has the potential to revolutionize diagnostic testing for infections of the CNS by allowing for widespread implementation. However, recent studies reporting false-negative and false-positive results raise concerns of negative impact on patients. In this interactive session, two speakers have taken a stance, one for ME panel testing and one against.

Session Objectives:

  • Discuss the epidemiology of meningitis and encephalitis and current diagnostic approaches.
  • Outline case examples to argue for or against widespread utilization of the ME panel.
  • Summarize key points that are important to be aware of when performing syndromic testing. 

Duration: 1.5 hr

Recording Date: November 1, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Alby&Dien Bard
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Friday November 2, 2018

Barbara A. Zehnbauer, PhD, Emory University School of Medicine, Atlanta, GA, USA

Session Description: Intended for trainees, new faculty, and intermediate-level laboratory scientists, this session will describe the functions and processing of submitted manuscripts through the journal editorial process. Aspects will include assessing the scope and mission of the journal, what editors look for, how to objectively convey the message of your work to the journal audience, how to constructively respond to reviewers’ comments, and the most common errors that result in manuscript rejection. Examples will focus on experiences from the Journal of Molecular Diagnostics but will be broadly applicable to other scientific publications.

Session Objectives:

  • Describe the attributes of a well-developed manuscript that concisely conveys one’s work.
  • Explain the common errors to avoid in manuscript submissions.
  • Outline the review process.
  • Identify constructive approaches to revise and improve manuscripts.

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Zehnbauer
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Visualizations for Genomic Data, the GTEx Experience
Jared L. Nedzel, Broad Institute, Cambridge, MA, USA

Katherine Huang, Broad Institute, Cambridge, MA, USA

Session Description: The practice of Molecular Pathology is continuing to grow in size and scope. This creates the need to more rapidly parse through complex datasets in order to scale the analysis and interpretation of genomic data. One of the approaches to this problem is to provide enhanced data visualization at multiple steps within the testing pipeline. This session will detail some of the common and newer tools used in data visualization. Specifically, it will provide examples of how these tools were implemented and how they led to novel insights that may have otherwise been missed.

Session Objectives:

  • Discuss current software and tools used in data visualization.
  • Demonstrate a use case for data visualization and describe how it led to novel insights.
  • Describe how to implement these tools within a laboratory. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available: 1 hr

Last day to purchase course and claim credit: November 1, 2019 

SAM Editor: Midhat Farooqi, PhD

ProductAddPrice
Nedzel&Huang (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

(Sponsored by the Professional Relations Committee)

Jill Hagenkord, MD, Color Genomics, Burlingame, CA, USA

Elissa Levin, MS, Helix, San Francisco, CA, USA

Danielle Bonadies, MS, My Gene Counsel, Branford, CT, USA

Altovise Ewing, PhD, 23and Me , Mountain View, CA, USA

Session Description: Consumer genetic tests have gained increasing prominence during the past several years. Offerings range from tests for ancestry and physical traits like eye color to medically relevant assays for the predisposition to disease. This session will discuss the evolving and future roles of consumer genetic tests in contemporary healthcare and examine key issues such as reporting, privacy, patient and provider comprehension, and regulation.

Session Objectives: 

  • Describe the current consumer genetic testing landscape.
  • Explore the positive and negative features of consumer genetic testing from different stakeholder perspectives.
  • Discuss potential roles for AMP and our members in this novel, alternative model of healthcare delivery. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
PRC
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Circulating Tumor DNA (ctDNA) Detection in CSF in a Patient with Metastatic Melanoma to the CNS
Andres Moon, MD, University of Washington, Seattle, WA, USA

An Unusual Driver Mutation in a Lung Adenocarcinoma
Erik Nohr, MD, Stanford Healthcare, Palo Alto, CA, USA

LMNA/NTRK1 Fusion in a Paravertebral Soft Tissue Mass
Yulei Shen, MD, PhD, Baylor College of Medicine, Houston, TX, USA

Recurrent Glioblastoma with Primary and Secondary Features in a Patient with a Deficiency of Mismatch Repair
Martin Powers, MD, University of California San Diego, San Diego, CA, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case’s clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
CS Solid Tumors
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Use of Molecular Testing to Predict Gonorrhea Treatment 
Jeffrey D. Klausner, MD, MPH, University of California, Los Angeles, CA, USA

Value of Molecular AST Methods for Bacteria: Are We There?
Romney M. Humphries, PhD, Accelerate Diagnostics, Tucson, AZ, USA

Session Description: Antimicrobial susceptibility testing methodologies used in clinical laboratories remains dominated by phenotypic testing. Molecular methods are becoming more common, including the use of whole genome sequencing, which may be able to predict antimicrobial susceptibility. This session will explore the feasibility of genomic susceptibility testing to predict appropriate treatment for Infectious Diseases.

Session Objectives:

  • Describe the utility of genomic susceptibility results.
  • Discuss the use of molecular test to determine antimicrobial susceptibility of Neisseria gonorrhea.
  • Discuss future directions in molecular antimicrobial susceptibility.

Duration: 1 hr

Recording Date: November 2, 2018

SAM available: 1 hr

Last day to purchase course and claim credit: November 1, 2019 

SAM Editors: Adrienne Bambach, PhD & Yi Ding, MD, PhD

ProductAddPrice
Klausner&Humphries (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Predictor of Response to PARP Inhibitors
Elizabeth M. Swisher, MD, University of Washington, Seattle, WA, USA

Leveraging Personalized Medicine for Diagnosis and Treatment of Pancreatic Cancer
Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, USA

Session Description: Human cancers are highly diverse, as evidenced by the complex pathologic classification systems that have evolved over the last century. Efforts to understand the genomics of solid tumors have only emphasized the complexity and demonstrated the biologic diversity of tumors even within individual morphologic categories. This results in significant implications for response to therapy and patient prognosis. This session will examine the genomic underpinnings of difficult-to-treat cancer types and will explore approaches to applying this knowledge to treatment selection.

Session Objectives: 

  • Examine the impact of germline cancer predisposition variants on therapeutic decisionmaking and patient counseling.
  • Describe the affect of common driver variants on the outcomes of patients with pancreatic cancer.
  • Explain the current role of in vitro models of human cancer in individualized patient care.
  • Recognize the significance of the BRCA-Fanconi anemia pathway in carcinogenesis and targeted therapeutics.

Duration: 1.5 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Swisher&Wolpin
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

G044 - Designing and Implementing NGS Tests for Inherited Disorders – a Practical Framework with Step-by-Step Guidance for Clinical Laboratories
Avni B. Santani, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

G025 - Verification of Very Small Copy Number Variants (Micro CNVs) Detected on Whole Genome CMA Analysis and Implications for Clinical Reporting
Ulrike P. Kappes, MPH, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, USA

G026 - Two-site Evaluation of a One-tube PCR/CE Assay that Resolves CAG Length Polymorphisms in Exon 1 of the HTT Gene
Sarah Statt, PhD, Asuragen, Austin, TX, USA

G021 - Brazilian Panorama of Whole Exome: Details of 315 Cases
Roberta Sitnik, PhD, Hospital Israelita Albert Einstein, São Paulo, Brazil

Session Description: Platform presentations of selected Genetics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Genetics Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Platform Genetics
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

H025 - Ultradeep Error Corrected Next-generation Sequencing (NGS) of ABL1 Kinase Domain Mutations in BCR-ABL1 Positive Malignancies
Nikhil Patkar, MD, Tata Memorial Center, Mumbai, Maharashtra, India

H041 -  Longitudinal Monitoring of AML Tumors with High-throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response
Dennis J. Eastburn, PhD, Mission Bio, Inc., South San Francisco, CA, USA

H014 - Mate Pair Sequencing: Ushering Cytogenetics Into the Era of Personalized Medicine
Nicole Hoppman, PhD, Mayo Clinic, Rochester, MN, USA

H039 - Donor-derived Clonal Hematopoiesis of Indeterminant Potential Mutations are Detected in Transplant Recipients after Allogeneic Hematopoietic Stem Cell Transplant
Jennifer Dunlap, MD, Oregon Health & Science University, Portland, OR, USA

Session Description: Platform presentations of selected Hematopathology abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Hematopathology Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Platform Heme
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

ID004 - Evaluation of a Novel Isothermal Amplification Assay for Detection and Genotyping of Human Papillomavirus in Formalin-fixed Paraffin-embedded Tissue of Oropharyngeal Carcinomas
Yi-Wei Tang, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ID012 - Comprehensive Solid Tumor Microbiome Profiling via Analysis of Unmapped Reads in Large Panel, Hybridization Capture-based NGS Assay Data
Chad M. Vanderbilt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ID063 - A Quantitative, Multiplexed RNA Detection Platform for Rapid Pathogen Identification and Phenotypic Antibiotic Susceptibility Testing (AST) using NanoString(™) Technology
Roby P. Bhattacharyya, MD, PhD, Broad Institute, Cambridge, MA, USA
Massachusetts General Hospital, Boston, MA, USA

ID007 - The Diagnostic Yield of Universal Pathogen Detection by Next-Generation Sequencing Compared to the Standard of Care in Patients with Pneumonia
Brittany A. Young, MD, PhD, University of Utah, Salt Lake City, UT, USA

Session Description: Platform presentations of selected Infectious Diseases abstracts.

Session Objectives: 

  • Analyze platform presentations of abstracts highlighted by the Infectious Diseases Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Platform ID
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

I025 - Identification of Viral Integration Sites in Cancer Genomes using Unmapped Reads in Targeted Next-Generation Sequencing Data
Anita S. Bowman, MS, Memorial Sloan Kettering Cancer Center, New York, NY, USA

I027 - Detection of Microsatellite Instability Using a Large Next-generation Sequencing Panel Across Diverse Tumor Types
Susan J. Hsiao, MD, PhD, Columbia University Medical Center, New York, NY, USA

I009 - Personalized Transcriptomic Drug Profiling in Non-small Cell Lung Cancer
Zachary Abrams, PhD, The Ohio State University, Athens, OH, USA

I034 - Assessing Cancer Diagnosis From Clinical Genomics Data Using Machine Learning 
Paul R. Hess, MD, PHD, University of Pennsylvania, Philadelphia, PA, USA

Session Description: Platform presentations of selected Informatics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Informatics Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Platform Info
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

ST002 - Analysis of Urinary Cell-free DNA for Early Detection and Surveillance of Bladder Cancer
Jonathan Dudley, MD, Stanford University, Stanford, CA, USA

ST055 - DNA Sequencing of Human, Epstein-Barr Virus, and Helicobacter Pylori Genomes to Classify and Monitor Gastric Adenocarcinoma

Margaret L. Gulley, MD, University of North Carolina, Chapel Hill, NC, USA

ST107 - Clinical Validation of MSK-ACCESS: An Ultrasensitive Next-generation Sequencing Assay for Liquid Biopsies in the Clinic
A. Rose Brannon, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ST144 - Prognosis Determined by Tumor Mutational Burden (TMB) Using Whole Exome Sequencing (WES)
Evan Fernandez, MS, Weill Cornell Medicine, New York, NY, USA

Session Description: Platform presentations of selected Solid Tumors abstracts.

Session Objectives:

  • Analyze presentations of abstracts highlighted by the Solid Tumors Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration: 1 hr

Recording Date: November 2, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Platform ST
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Microbiome Changes with Infectious Complications During Stem Cell Transplantation
Ying Taur, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The Intestinal Virome: From Chronic Inflammation to Bacteriophage Therapy Targeting Multidrug Resistant Bacteria
Breck A. Duerkop, PhD, University of Colorado School of Medicine, Aurora, CO, USA

Session Description: This plenary session will present data from two speakers illustrating the microbial communities in our bodies and the role microbiomes (viromes) play in human health and diseases. This session will explain the reasons that the human microbiome is as important as the human genome.

Session Objectives:

  • Describe how the gut microbiome is disrupted during stem cell transplantation, and its impact on patient outcomes.
  • Outline the connection between the microbiome and stem cell immunity, and how that could inform on other avenues of human health.
  • Summarize interventional studies aimed at maintaining or restoring microbiome health to patients in the setting of stem cell transplantation.
  • Discuss how the molecular characterization of bacteriophage infection mechanisms may lead to novel antibacterial therapeutics. 

Duration: 1.5 hr

Recording Date: November 2, 2018

SAM available: 0.75 hr (only Breck A. Duerkop's session is eligible for SAM)

Last day to purchase course and claim credit: November 1, 2019 

SAM Editor: Adrienne Bambach, PhD

ProductAddPrice
Taur&Duerkop (+SAM)
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

CRISPR/Cas9 Targeting and Inactivation of Viral DNA Genomes
Bryan R. Cullen, PhD, Duke University Medical Center, Durham, NC, USA

Programmable RNA-targeting CRISPR-Cas Enzymes for RNA Detection and Therapeutics
Mitchell R. O'Connell, PhD, University of Rochester, Rochester, NY, USA

Session Description: A number of DNA viruses, including Hepatitis B virus (HBV) and Human papillomavirus (HPV), cause severe, chronic diseases in humans that are difficult to cure using currently available approaches. One possible novel treatment approach involves the cleavage and destruction of the long-lived viral DNA genomes that maintain these diseases using DNA editing. This session will discuss data obtained in cultured cells and animals that demonstrate significant reductions in viral load after targeting of the HBV or HPV16 DNA genome using CRISPR/Cas. The aim of this session is to also present studies performed to understand the molecular mechanisms by which CRISPR-Cas proteins such as Cas9 and Cas13 are able to target RNA, and how these properties can be exploited to develop a number of applications including RNA detection, RNA imaging, and manipulation of RNA function in health and disease.

Session Objectives:

  • Summarize the molecular basis for persistent infections caused by DNA viruses.
  • Outline evidence that CRISPR/Cas represents a potentially useful approach to the treatment and possibly even cure of otherwise refractory DNA virus infections.
  • Discuss the molecular mechanisms of specific interaction between CRISPR/Cas9 and Cas13 adaptive immune systems and RNA.
  • Outline the use of these properties to develop a number of applications including RNA detection, RNA imaging and manipulation of RNA function in health and disease.

Duration: 1.5 hr

Recording Date: November 2, 2018

SAM available: 1.5 hr

Last day to purchase course and claim credit: November 1, 2019 

SAM Editor: Cory Broehm, MD

ProductAddPrice
Cullen&O'Connell (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Industry Perspective
Robert L. Nussbaum, MD, Invitae Corporation, San Francisco, CA, USA

Academic Perspective
Wayne W. Grody, MD, PhD, University of California, Los Angeles, CA, USA

Session Description: This session will present advances in next-generation sequencing (NGS) in CLIA-certified and CAP-accredited laboratories to improve diagnostic testing. Collaborative efforts between Invitae, the Laboratory of Molecular Medicine, and the National Institute of Standards and Technology resulted in a framework for assessment of which variants are at risk for being false positives and are in need of orthogonal confirmation. Unique cross-disciplinary interpretation and reporting decisions made by a “Clinical Genomics Board” at UCLA reveal surprising results and lessons learned.

Session Objectives:

  • Recognize the large amount of data needed for accurate assessment of false positive rates.
  • Predict quality factors and genome context that contribute to false positive rates.
  • Assess clinical utility, diagnostic yield, interpretive challenges, and reimbursement issues for patients with undiagnosed disorders.
  • Summarize ethical dilemmas raised by clinical NGS.

Duration: 1.5 hr

Recording Date: November 2, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Nussbaum&Grody
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

"In Silico" Proficiency Testing
John D. Pfeifer, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

In Silico Proficiency Testing for Clinical Next Generation Sequencing
Karl V. Voelkerding, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Session Description: One of the challenges unanimously faced by clinical laboratories is procuring samples containing the desired types of sequence variant for NGS assay validation and proficiency testing (PT); in particular, uncommon and difficult indels and complex variants. In contrast to physical samples, well-curated and validated in silico sequence data is an invaluable and replenishable resource with many potential clinical use cases. This session will discuss the strength and limitations of in silico sequencing data with insights on current and future clinical application for assay validation and PT.

Session Objectives:

  • Define in silico sequence datasets and how are they generated, including the tools and software developed for this purpose.
  • Describe the strengths and limitations of in silico datasets.
  • Discuss the current and future applications of in silico data for assay validation and PT. 

Duration1.5 hr

Recording Date: November 2, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Pfeifer&Voelkerding
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Saturday November 3, 2018

Thomas W. Prior, PhD, Case Western Reserve University, Cleveland, OH, USA

Session Description: The Genetic Puzzlers are back at the AMP meeting this year. AMP members are invited to submit genetic case puzzlers for presentation. Cases should facilitate discussion and should highlight interesting clinical and technical issues. The session provides an excellent forum to share experiences and teach others how they handled a challenging genetic case. Those submitting accepted cases will be invited to present and provide a learning objective.

Session Objectives: 

  • Those submitting accepted cases will be invited to present and provide a learning objective.

Duration: 1 hr

Recording Date: November 3, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Prior
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Jeremy Segal, MD, PhD, University of Chicago, Chicago, IL, USA

Dara Aisner, MD, PhD, University of Colorado, Denver, CO, USA

Session Description: This session will focus on the advantages of an inter-institutional consortium of academic labs for large panel NGS oncology tests. The speakers will discuss efforts to collaborate on design parameters and specifications as well as sharing techniques and methodologies for library preparation and bioinformatic solutions. The advantages and challenges associated with multi-institutional commercial-scale reagent purchasing and technical optimization will also be emphasized.

Session Objectives:

  • Review the current status of the genomic oncology diagnostics space, including obstacles and incentives for inter-institutional collaboration 
  • Discuss the basic principles of capture-based next generation sequencing assays, including various options for custom development.
  • Summarize design considerations for largescale hybrid capture probe purchases, including refinement via directed pilot studies.
  • Describe the potential of multi-institutional assay design and bioInformatics collaborations to help lower costs and promote performance standardization. 

Duration1 hr

Recording Date: November 3, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Segal&Aisner
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Identification of a Rare Germline POT1 Mutation by Targeted Next-Generation Sequencing of a Splenic Marginal Zone Lymphoma
Audrey Jajosky, MD, PhD, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

Identification of Acute Leukemia Risk Mutations in a Child with Severe Congenital Neutropenia
Jennifer Yoest, MD, Washington University School of Medicine in St. Louis, St. Louis, MO, USA              

Whole Genome Sequencing Identifies Cryptic High-Risk Cytogenetic Findings In A Patient With Acute Myeloid Leukemia
Michael Alberti, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, USA

A Case of Myeloid Neoplasm with Germline Predisposition: Connecting the Clinical, Laboratory, Morphology and Molecular Dots
Fatima Zahra Jelloul, MD, MD Anderson Cancer Center, Houston, TX, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case’s clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.

Duration1 hr

Recording Date: November 3, 2018

SAM available: SAM is not available for this session

ProductAddPrice
CS Heme
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

TT074 - Multi-Patient Longitudinal Monitoring of Cancer Mutations from Circulating DNA of Using Personalized Single Color Digital PCR Assays
Christina M. Bouwens, Stanford University, Stanford, CA, USA

TT059 - Cell-free DNA Allograft Rejection Monitoring Using Low-coverage Whole Genome Sequencing
Niklas Krumm, MD, PhD, University of Washington, Seattle, WA, USA

TT070 - Universal Design and Rapid PCR for Genotyping by High Resolution Melting
Jessica Houskeeper, MRes , University of Utah, Salt Lake City, UT, USA

TT046 - The NIH Genetic Testing Registry (GTR): Test Methodologies as a Sensor of the Precision Medicine Environment
Adriana Malheiro, MS, National Center for Biotechnology Information, NIH, Bethesda, MD, USA

Session Description: Platform presentations of selected Technical Topics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Technical Topics leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors. 

Duration1 hr

Recording Date: November 3, 2018

SAM available: SAM is not available for this session

ProductAddPrice
Platform TT
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Opportunities and Challenges in Laboratory Stewardship: Leaders Apply Here
Gary Procop, MD, Cleveland Clinic, Cleveland, OH, USA

Session Description: This presentation will focus mainly on challenges regarding the clinical utility of, and opportunities for, molecular diagnostics tests in Pathology and Lab Medicine Laboratories.

Session Objectives: 

  • Discuss interventions undertaken to improve care delivery through laboratory stewardship.
  • Describe additional emphases on laboratory leadership and collaboration with clinical colleagues, as well as the importance of communication, professionalism, and a systembased approach to problem solving.
  • Summarize evidence presented from described interventions on promoting healthcare affordability that directly improve quality of health care delivered. 

Duration1 hr

Recording Date: November 3, 2018

SAM available: 1 hr

Last day to purchase course and claim credit: November 1, 2019

SAM Editor: Adrienne Bambach, PhD

ProductAddPrice
Procop (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Artificial Intelligence in Cancer Genomics and Therapy
Olivier Elemento, PhD, Weill Cornell Medicine - Englander Institute for Precision Medicine, New York, NY, USA

Probabilistic Graphical Models for Integrative Analysis of Pathomics Data
Panagiotis Benos, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Session Description: From sequencing to phenotypic information, the amount of data within the molecular diagnostics laboratory is increasing at an ever-rapid pace with the emergence of new technologies and structured data sources. While dealing with this influx of information requires new analyses, it also presents an opportunity to learn from the data to provide novel insights that would otherwise be difficult to identify. This session will present an overview of these analysis methods, including artificial intelligence and machine learning approaches, and their current and future applications in the fields of genomics and molecular diagnostics for improving patient care.

Session Objectives:

  • Describe the concepts of artificial intelligence and machine learning.
  • Summarize the emergence of big data in genomics, including the challenges and opportunities associated with large-scale analyses.
  • Examine the current and future use of these tools in the genomics and molecular pathology practice.

Duration1.5 hr

Recording Date: November 3, 2018

SAM available: 0.75 hr (Only Olivier Elemento's talk is eligible for SAM)

Last day to purchase course and claim credit: November 1, 2019

SAM Editor: Ronald M. Przygodzki, MD

ProductAddPrice
Elemento&Benos (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Clinical Applications of Digital PCR 
Maria Arcila, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Liquid Biopsy for Solid Tumors: Promises and Perils
Mark Routbort, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session Description: This session will focus on the implementation & validation of a cirulating cell free DNA assay for sequence variants, copy number variations, and fusions. The speakers will discuss the clinical indications for ccfDNA testing with an emphasis on the importance of clinical correlation and the pitfalls that may arise when viewing ccfDNA data in isolation. Challenges such as interpretation of somatic versus germline variants as well as interpretation of variants arising in the context of clonal hematopoiesis wil be emphasized.

Session Objectives:

  • Recognize the “cellular compartment of origin” challenge inherent to ccfDNA testing.
  • Generate approaches for dealing with likely germline findings of cancer susceptibility.
  • Discuss the pre-analytic and standardization challenges associated with ctDNA.
  • Summarize the clinical utility of dPCR in ctDNA testing. 

Duration1.5 hr

Recording Date: November 3, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Arcila&Routbort
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Cancer Genomics Visualization across Scales: Nucleotides to Cohorts
Nils Gehlenborg, PhD, Harvard Medical School, Boston, MA, USA

Data Commons for Precision Cancer Medicine
Ethan Cerami, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Session Description: Data visualization is an invaluable technology for gaining insights into the results of complex genomics analyses. Interactive visual data exploration and communication are highly effective strategies that are largely unexplored in the practice of molecular pathology and precision medicine. This session will highlight the role of data visualization in exploring, interpreting, and communicating high-complexity molecular data in patient care.

Session Objectives:

  • Describe the concepts and transformative power of data visualization for exploration and communication of genomics data.
  • Summarize how visual data exploration and communication can streamline the practice of precision medicine.
  • Discuss the potential-use cases of data visualization in current clinical practice. 

Duration1.5 hr

Recording Date: November 3, 2018

SAM available: 0.75 hr (Only Ethan Cerami's talk is eligible for SAM)

Last day to purchase course and claim credit: November 1, 2019

SAM Editor: Cory Broehm, MD

ProductAddPrice
Gehlenborg&Cerami (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

The Role of Enterovirus D68 in Acute Flaccid Myelitis
Kevin Messacar, MD, University of Colorado/Children's Hospital Colorado, Aurora, CO, USA

Epidemiology, Surveillance, and Diagnosis of Enterovirus D68
Samuel Dominguez, MD, PhD, University of Colorado/Children's Hospital Colorado, Aurora, CO, USA

Session Description: Large outbreaks of enterovirus D68 (EV-D68) in 2014 and 2016 were widespread in North America and other regions and coincided with associated cases of acute flaccid myelitis (AFM), a polio-like paralysis that is due to lesions in the anterior horn of the spinal cord. This session will discuss epidemiological and biological evidence supporting the association between EV-D68 and AFM. In addition, current recommendations related to diagnostic testing will be discussed.

Session Objectives:

  • Summarize current understanding of the epidemiology and disease associations of EVD68.
  • Describe evidence supporting and lacking in the causal relationship between enterovirus D68 and acute flaccid myelitis.
  • Discuss current laboratory testing options for EV-D68. 

Duration1.5 hr

Recording Date: November 3, 2018

SAM available: 1.5 hr

Last day to purchase course and claim credit: November 1, 2019

SAM Editor: Alan Brown, MD

ProductAddPrice
Messacar&Dominguez (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

AMP Guidelines for Validating Next Generation Sequencing Bioinformatics Pipelines
Somak Roy, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Alexis B. Carter, MD, Children's Healthcare of Atlanta, Atlanta, GA, USA

Session Description: BioInformatics pipelines are an integral component of next generation sequencing (NGS) assay. There is, however, significant variability in how bioInformatics pipelines are validated in the global molecular genetics and pathology community in the absence of published guidelines. To address this unmet need, the Association of Molecular Pathology (AMP), with liaison representation from the College of American Pathologists (CAP) and the American Medical Informatics Association (AMIA), has developed a set of best practice consensus recommendations for the validation of clinical NGS bioInformatics pipelines. This sessions will discuss the guidelines and approaches to implementing these guidelines in the molecular pathology laboratory.

Session Objectives:

  • Apply the recommendations from the recent joint consensus (AMP, CAP, AMIA) guideline for design, optimization and familiarization, and clinical validation of the NGS bioInformatics pipeline.
  • Use the recommendations to successfully create a sample/variant cohort for clinical validation of the bioInformatics pipeline.
  • Employ strategies to incorporate security of protected health information, preservation of sample identity, and data integrity of sequence files during validation and implementation of the pipeline. 

Duration1.5 hr

Recording Date: November 3, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Roy&Carter
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, The Ohio State University, Columbus, OH, USA

Towards a Genomic Classification of T Cell Malignancies: Opportunities for Precision Medicine
Megan S. Lim, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

Session Description: For mature T-cell lymphomas, the recent application of genomic technologies has identified recurrent genetic alterations and enhanced our understanding of the pathogenetic mechanisms underlying this poorly understood category of non-Hodgkin lymphomas. Dr. Lim will discuss the potential relevance of these findings to diagnosis, prognosis, and therapy. Targeted small molecule therapeutics have transformed the therapy of chronic lymphocytic leukemia (CLL). While most patients achieve durable remissions, many with high genomic risk disease will relapse, and their outcomes are poor. Dr. Woyach will discuss known and suspected mechanisms of resistance to targeted therapies as well as pathways and agents with the potential to prevent or treat resistant disease.

Session Objectives:

  • Summarize the genetic diversity of mature T-cell malignancies to improve diagnosis and discover opportunities for tailored therapy.
  • Discuss targeted therapy for chronic lymphocytic leukemia (CLL), mechanisms of resistance to these therapies, especially Bruton tyrosine kinase (BTK) inhibitors.
  • Describe novel therapies with the potential to overcome resistance to BTK inhibitors.

Duration1.5 hr

Recording Date: November 3, 2018

SAM available: 1.5 hr

Last day to purchase course and claim credit: November 1, 2019

SAM Editor: Alan Brown, MD

ProductAddPrice
Woyach&Lim (+SAM)
AMP Regular Member: $60.00
AMP Technologist Member: $60.00
AMP Associate Member: $60.00
Non-member Price: $199.00

Metagenomic Mapping of the Phones of AMP 2018
Christopher E. Mason, PhD, Weill Cornell Medicine, New York, NY, USA

Session Description: Have you ever been curious to know what microorganisms you are harboring on your mobile phone? If so, this interactive event is what you’ve been waiting for. Similar to his past work mapping out the microbiome of the New York City Subway, Dr. Chris Mason and his team will be performing metagenomic sequencing on mobile phone samples of volunteers at the beginning of the meeting and the data will be presented during this session.

Session Objectives:

  • Review the methodology used for metagenomic analysis of environmental samples.
  • Determine the microbiome of AMP attendee’s mobile phones and discuss the degree of microbial diversity.
  • Discuss the significance of mapping out the community of microorganisms that inhabit public spaces. 

Duration: 1.5 hr

Recording Date: November 3, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Mason (+SAM)
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Clinical Implications of Mutational Load and Signatures on Replication Repair Deficiency in Cancer
Uri Tabori, MD, PhD, Hospital for Sick Children, Toronto, Ontario, Canada

Hypermutation in Cancer: Burden and Signatures of Mutational Processes
Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Session Description: Oncogenic driver mutations have emerged as important targets for targeted kinase inhibitor therapy, but alterations in these genes often represent only a small fraction of the DNA substitutions present in human cancers. Examination of both the overall number and kind of DNA substitutions in tumors can lend insight into etiologies of mutagenesis and may predict responses to immunooncology-based therapies. Both whole exome and targeted panel data can be leveraged for broader analysis of tumor mutation burden and mutational signatures. This session will focus on approaches to TMB calculation and mutational signature detection including an emphasis on the clinical implications of these approaches.

Session Objectives:

  • Compare and contrast analysis of tumor mutation burden obtained using exome data versus smaller panels.
  • Summarize how tumor mutation burden correlates with response to immune-oncology treatment.
  • Discuss how mutational signatures are derived from sequencing data, including from exome and targeted sequencing data.
  • Describe the clinical significance of determining germline and somatic replication repair deficiency variants.

Duration1.5 hr

Recording Date: November 3, 2018

SAM available:SAM is not available for this session

ProductAddPrice
Tabori&Zehir
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Individual topic purchase: Selected
Products
AM18 Recording +SAM
AMP Regular Member: $525.00
AMP Technologist Member: $525.00
AMP Associate Member: $525.00
Non-member Price: $749.00